US5595997A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
Assignee: University of Massachusetts Boston
•
Filing: 1994-12-30
•
Granted: 1997-01-21
•
Expires: 2014-12-30
Abstract
Abstract Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Inventors
- 👤 A. K. Gunnar Aberg
- 👤 John R. McCullough
- 👤 Emil R. Smith
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 11:34
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445; A61K31/4523; A61K31/4545; A61K31/13; A61K31/135; A61K31/137; A61K31/451; A61K45/00; A61K45/06; A61P; A61P11/00; A61P11/02; A61P11/06; A61P17/00; A61P25/00; A61P25/04; A61P27/00; A61P27/02; A61P27/14; A61P27/16; A61P29/00; A61P3/00; A61P3/08; A61P3/10; A61P31/00; A61P31/12; A61P31/14; A61P31/16; A61P37/00; A61P37/08; A61P9/00; A61P9/10
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
41 words
A method of treating allergic rhinitis in a human while avoiding the concomitant liability of adverse side-effects associated with the administration of non-sedating antihistamines, comprising administering to said human a therapeutically effective amount of descarboethoxyloratadine or a pharmaceutically acceptable salt thereof.
Claim 2
Independent Claim
41 words
A method of treating allergic rhinitis in a human while avoiding the concomitant liability of adverse side-effects associated with the administration of non-sedating antihistamines, comprising administering to said human a therapeutically effective amount of descarboethoxyloratadine or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein said adverse side-effect is cardiac arrhythmia or tumor promotion.
Claim 4
Dependent Claim
19 words
The method of claim 1 wherein said human has a higher than normal propensity for or incidence of cancer.
Claim 5
Dependent Claim
18 words
The method of claim 1, wherein interaction between DCL and a drug that inhibits cytochrome P450 is avoided.
Claim 6
Dependent Claim
24 words
The method of claim 1 wherein the amount of DCL administered is from about 0.1 mg to less than about 10 mg per day.
Claim 7
Dependent Claim
22 words
The method of claim 5 wherein the amount of DCL administered is from about 0.1 mg to about 5 mg per day.
Claim 8
Dependent Claim
25 words
The method of claim 1 wherein the amount of said DCL or a pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
WO1985003707A1
Cited
US4659716A
Cited
US5089496A
Cited
EP0288640A1
Cited
US5019591A
Cited
WO1992000293A1
Cited
WO1992011034A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-01-21 | 2000-07-22 | 2001-01-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-01-21 | 2004-07-22 | 2005-01-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-01-21 | 2008-07-22 | 2009-01-21 | $7700.00 | Window Closed / Lapsed |